Benzinga
Benzinga
Benzinga
lunes, septiembre 14

GeneDx Holdings Corp

WGSNASDAQ
Trade with Public
Trade with Public
$85.27
1.311.55%
al cierre: Sep 10, 5:00 PM EST
$84.44
0.480.57%
Premercado: 8:26 AM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

GeneDx Holdings Analyst Price Targets

Wall Street analyst price targets and consensus rating for GeneDx Holdings (WGS).

Price Target Range — 11 Quarters

Analyst Consensus — 10 Analysts

9Buy
1Hold
Consensus RatingBuy# Analysts10Avg. Consensus PT$88Upside to Avg. PT+3.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →
DateFirmAnalystActionRating ChangePrice Target
Aug 4, 2026Canaccord GenuityKyle MiksonPT RaiseBuy$75→$90
Aug 4, 2026BTIGMark MassaroMaintainedBuy$90
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $90

Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the price target from $75 to $90.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on GeneDx Holdings, Maintains $90 Price Target

BTIG analyst Mark Massaro reiterates GeneDx Holdings (NASDAQ:WGS) with a Buy and maintains $90 price target.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $74

Guggenheim analyst Subbu Nambi maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the price target from $70 to $74.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on GeneDx Holdings, Raises Price Target to $63

Piper Sandler analyst David Westenberg maintains GeneDx Holdings (NASDAQ:WGS) with a Overweight and raises the price target from $50 to $63.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on GeneDx Holdings, Lowers Price Target to $75

Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and lowers the price target from $100 to $75.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on GeneDx Holdings, Lowers Price Target to $75

Wells Fargo analyst Brandon Couillard maintains GeneDx Holdings (NASDAQ:WGS) with a Overweight and lowers the price target from $155 to $75.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved